Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to $19.2 million.

  • Avalo Therapeutics' Operating Expenses rose 4643.78% to $19.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.7 million, marking a year-over-year increase of 471.88%. This contributed to the annual value of $69.0 million for FY2024, which is 13553.54% up from last year.
  • According to the latest figures from Q3 2025, Avalo Therapeutics' Operating Expenses is $19.2 million, which was up 4643.78% from $19.3 million recorded in Q2 2025.
  • Avalo Therapeutics' Operating Expenses' 5-year high stood at $32.8 million during Q1 2024, with a 5-year trough of $4.0 million in Q3 2023.
  • Moreover, its 5-year median value for Operating Expenses was $13.5 million (2024), whereas its average is $15.5 million.
  • In the last 5 years, Avalo Therapeutics' Operating Expenses tumbled by 6327.62% in 2023 and then skyrocketed by 25358.8% in 2024.
  • Over the past 5 years, Avalo Therapeutics' Operating Expenses (Quarter) stood at $18.2 million in 2021, then tumbled by 46.37% to $9.8 million in 2022, then dropped by 15.61% to $8.2 million in 2023, then surged by 64.09% to $13.5 million in 2024, then soared by 42.18% to $19.2 million in 2025.
  • Its Operating Expenses was $19.2 million in Q3 2025, compared to $19.3 million in Q2 2025 and $14.7 million in Q1 2025.